Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor

Bioengineered

Volumn 8, Issue 5, 2017, Pages 501-510

  Nickho, Hamid ^a,b   Younesi, Vahid ^c,d   Aghebati Maleki, Leili ^a,b   Motallebnezhad, Morteza ^a,b   Majidi Zolbanin, Jafar ^a,b   Movassagh Pour, Aliakbar ^a,b   Yousefi, Mehdi ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Pishtaz Teb Medical Co   (Iran)

^d ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

breast cancer; Fzd7; phage display; scFv; Wnt

Indexed keywords

LIPOCORTIN 5; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; FRIZZLED PROTEIN; FZD7 PROTEIN, HUMAN;

ARTICLE; CELL PROLIFERATION; COLONY FORMING UNIT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; HUMAN; HUMAN CELL; MTT ASSAY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SCFV GENE; APOPTOSIS; CELL SURFACE DISPLAY; DRUG EFFECTS; DRUG SCREENING; IMMUNOASSAY; IMMUNOLOGY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURFACE DISPLAY TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FRIZZLED RECEPTORS; HUMANS; IMMUNOASSAY; SINGLE-CHAIN ANTIBODIES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85010693192     PISSN: 21655979     EISSN: 21655987     Source Type: Journal    
DOI: 10.1080/21655979.2016.1255383     Document Type: Article

References (47)

1. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis 2010; 32:35-8; PMID:21778573; http://dx.doi.org/10.3233/BD-2010-0307
2. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan Y, Deng X, Chen L, Kim CC, Lau S, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011; 30:4437-46; PMID:21532620; http://dx.doi.org/10.1038/onc.2011.145
3. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer—current status and future directions. Ann Oncol 2009; 20:1913-27; PMID:19901010; http://dx.doi.org/10.1093/annonc/mdp492
4. Dann CE, Hsieh JC, Rattner A, Sharma D, Nathans J, Leahy DJ. Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. Nature 2001; 412:86-90; PMID:11452312; http://dx.doi.org/10.1038/35083601
5. Bhanot P, Brink M, Samos CH, Hsieh JC, Wang Y, Macke JP, Andrew D, Nathans J, Nusse R. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 1996; 382:225-30; PMID:8717036
6. Schulte G. International union of basic and clinical pharmacology. LXXX. The class Frizzled receptors. Pharmacol Rev 2010; 62:632-67; PMID:21079039; http://dx.doi.org/10.1124/pr.110.002931
7. Miller JR. The wnts. Genome Biol 2002; 3:3001
8. Saini S, Majid S, Dahiya R. The complex roles of Wnt antagonists in RCC. Nat Rev Urol 2011; 8:690-9; PMID:22025172
9. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 2004; 5:691-701; PMID:15372092; http://dx.doi.org/10.1038/nrg1427
10. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006; 127:469-80; PMID:17081971; http://dx.doi.org/10.1016/j.cell.2006.10.018
11. King TD, Zhang W, Suto MJ, Li Y. Frizzled7 as an emerging target for cancer therapy. Cell Signal 2012; 24:846-51; PMID:22182510; http://dx.doi.org/10.1016/j.cellsig.2011.12.009
12. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 2000; 407:535-8; PMID:11029008; http://dx.doi.org/10.1038/35035124
13. He X, Saint-Jeannet JP, Wang Y, Nathans J, Dawid I, Varmus H. A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 1997; 275:1652-4; PMID:9054360; http://dx.doi.org/10.1126/science.275.5306.1652
14. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8:387-98; PMID:18432252; http://dx.doi.org/10.1038/nrc2389
15. Röhrs S, Kutzner N, Vlad A, Grunwald T, Ziegler S, Müller O. Chronological expression of Wnt target genes Ccnd1, Myc, Cdkn1a, Tfrc, Plf1 and Ramp3. Cell Biol Int 2009; 33:501-8; PMID:19353769; http://dx.doi.org/10.1016/j.cellbi.2009.01.016
16. Zhang J, Gill AJ, Issacs JD, Atmore B, Johns A, Delbridge LW, Lai R, McMullen TP. The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer. Hum Pathol 2012; 43:1044-50; PMID:22204713; http://dx.doi.org/10.1016/j.humpath.2011.08.013
17. Kormish JD, Sinner D, Zorn AM. Interactions between SOX factors and Wnt/â‐catenin signaling in development and disease. Dev Dyn 2010; 239:56-68; PMID:19655378
18. Liu P, Ramachandran S, Seyed MA, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006; 66:4011-9; PMID:16618720; http://dx.doi.org/10.1158/0008-5472.CAN-05-3055
19. Song GD, Sun Y, Shen H, Li W. SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients. Tumor Biol 2015; 36:4167-73; PMID:25592378; http://dx.doi.org/10.1007/s13277-015-3051-9
20. Wang B, Li Y, Tan F, Xiao Z. Increased expression of SOX4 is associated with colorectal cancer progression. Tumor Biol 2016; 37:9131-7; PMID:26768610; http://dx.doi.org/10.1007/s13277-015-4756-5
21. Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, Jonatan D, Zorn AM, Wells JM. Sox17 and Sox4 differentially regulate β-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol 2007; 27:7802-15; PMID:17875931; http://dx.doi.org/10.1128/MCB.02179-06
22. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-67; PMID:21633166; http://dx.doi.org/10.1172/JCI45014
23. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2002; 2:1; PMID:11872147; http://dx.doi.org/10.1186/1471-213X-2-8
24. Kirikoshi H, Sekihara H, Katoh M. Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. Int J Oncol 2001; 19:111-5; PMID:11408930
25. Merle P, Kim M, Herrmann M, Gupte A, Lefrançois L, Califano S, Trépo C, Tanaka S, Vitvitski L, de la Monte S, et al. Oncogenic role of the frizzled-7/β-catenin pathway in hepatocellular carcinoma. J Hepatol 2005; 43:854-62; PMID:16098625; http://dx.doi.org/10.1016/j.jhep.2005.05.018
26. Samaei NM, Yazdani Y, Alizadeh-Navaei R, Azadeh H, Farazmandfar T. Promoter methylation analysis of WNT/β-catenin pathway regulators and its association with expression of DNMT1 enzyme in colorectal cancer. J Biomed Sci 2014; 21:1; PMID:24397824; http://dx.doi.org/10.1186/s12929-014-0073-3
27. Willats WG. Phage display: practicalities and prospects. Plant Mol Biol 2002; 50:837-54; PMID:12516857; http://dx.doi.org/10.1023/A:1021215516430
28. Liu R, Yuan B, Emadi S, Zameer A, Schulz P, McAllister C, Lyubchenko Y, Goud G, Sierks MR. Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity. Biochemistry 2004; 43:6959-67; PMID:15170333; http://dx.doi.org/10.1021/bi049933o
29. Juarez-Gonzalez V, Riano-Umbarila L, Quintero-Hernandez V, Olamendi-Portugal T, Ortiz-Leon M, Ortiz E, Possani LD, Becerril B. Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2. J Mol Biol 2005; 346:1287-97; PMID:15713481; http://dx.doi.org/10.1016/j.jmb.2004.12.060
30. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Pope SH, Riordan GS, Whitlow M. Single-chain antigen-binding proteins. Science 1988; 242:423-6; PMID:3140379; http://dx.doi.org/10.1126/science.3140379
31. Luo D, Mah N, Wishart D, Zhang Y, Jacobs F, Martin L. Construction and expression of bi-functional proteins of single-chain Fv with effector domains. J Biochem 1996; 120:229-32; PMID:8889803; http://dx.doi.org/10.1093/oxfordjournals.jbchem.a021402
32. Nejatollahi F, Ranjbar R, Younesi V, Asgharpour M. Deregulation of HER2 downstream signaling in breast cancer cells by a cocktail of anti-HER2 scFvs. Oncol Res 2013; 20:333-40; http://dx.doi.org/10.3727/096504013X13657689382734
33. Gupta P, Han SY, Holgado-Madruga M, Mitra SS, Li G, Nitta RT, Wong AJ. Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol 2010; 10:72; PMID:20925961; http://dx.doi.org/10.1186/1472-6750-10-72
34. Albrecht H, Denardo G, Denardo S. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Q J Nucl Med Mol Imaging 2007; 51:304-13; PMID:17464275
35. Younesi V, Nejatollahi F. Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells. Int Immunopharmacol 2014; 23:624-32; PMID:25466271; http://dx.doi.org/10.1016/j.intimp.2014.10.015
36. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 2001; 3:683-6; PMID:11433302; http://dx.doi.org/10.1038/35083081
37. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular β-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci 1995; 92:3046-50; http://dx.doi.org/10.1073/pnas.92.7.3046
38. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci 1999; 96:5522-7; http://dx.doi.org/10.1073/pnas.96.10.5522
39. Su Y, Simmen RC. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates β-catenin signaling in mammary epithelial cells. Carcinogenesis 2009; 30:331-9; PMID:19073877; http://dx.doi.org/10.1093/carcin/bgn279
40. Bilir B, Kucuk O, Moreno CS. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med 2013; 11:280; PMID:24188694; http://dx.doi.org/10.1186/1479-5876-11-280
41. Pramoonjago P, Baras A, Moskaluk C. Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. Oncogene 2006; 25:5626-39; PMID:16636670; http://dx.doi.org/10.1038/sj.onc.1209566
42. Gehrke I, Gandhirajan RK, Kreuzer KA. Targeting the WNT/β-catenin/TCF/LEF1 axis in solid and haematological cancers: multiplicity of therapeutic options. Euro J Cancer 2009; 45:2759-67; PMID:19729298; http://dx.doi.org/10.1016/j.ejca.2009.08.003
43. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004; 6:7-14; PMID:15068666; http://dx.doi.org/10.1016/S1476-5586(04)80048-4
44. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci 2012; 109:11717-22; http://dx.doi.org/10.1073/pnas.1120068109
45. Claret FX, Vu TT. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol 2012; 2:62; PMID:22720269
46. King TD, Suto MJ, Li Y. The wnt/â‐catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem 2012; 113:13-8; PMID:21898546; http://dx.doi.org/10.1002/jcb.23350
47. Sadreddini S, Seifi-Najmi M, Ghasemi B, Kafil HS, Alinejad V, Sadreddini S, Younesi V, Jadidi-Niaragh F, Yousefi M. Design and construction of immune phage antibody library against Tetanus neurotoxin: Production of single chain antibody fragments. Human Antibodies 2015; 23:73-9; PMID:27472865; http://dx.doi.org/10.3233/HAB-150287